Proteasomal inhibition after injury prevents fibrosis by modulating TGF-β1 signalling

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Thorax

• Publication date

  2011-09-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1136/thoraxjnl-2011-200717PMID 21921091PMCID PMC3595535
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Leptin promotes fibroproliferative acute respiratory distress syndrome by inhibiting peroxisome proliferator-activated receptor-γ.

  2011cited by this paper
• PPARγ Downregulation by TGFß in Fibroblast and Impaired Expression and Function in Systemic Sclerosis: A Novel Mechanism for Progressive Fibrogenesis

  2010cited by this paper
• Challenges in translating preclinical studies to effective drug therapies in idiopathic pulmonary fibrosis.

  2010cited by this paper
• Cell Injury , Repair , Aging and Apoptosis Essential Roles for Early Growth Response Transcription Factor Egr-1 in Tissue Fibrosis and Wound Healing

  2010cited by this paper
• Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

  2010cited by this paper
• Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.

  2010cited by this paper
• Thorax

  2009cited by this paper
• Essential roles for early growth response transcription factor Egr-1 in tissue fibrosis and wound healing.

  2009cited by this paper
• Alveolar extracellular 20S proteasome in patients with acute respiratory distress syndrome.

  2009cited by this paper
• Mitochondrial Complex III-generated Oxidants Activate ASK1 and JNK to Induce Alveolar Epithelial Cell Death following Exposure to Particulate Matter Air Pollution*

  2009cited by this paper
• Peroxisome proliferator‐activated receptor‐γ abrogates Smad‐dependent collagen stimulation by targeting the p300 transcriptional coactivator

  2009cited by this paper
• The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments.

  2009cited by this paper
• PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis.

  2008cited by this paper
• Fat and beyond: the diverse biology of PPARgamma.

  2008cited by this paper
• In vivo investigations on anti-fibrotic potential of proteasome inhibition in lung and skin fibrosis.

  2008cited by this paper
• Cooperative relationship between pharmaceutical companies, academia, and media explains sharp decrease in frequency of pulmonary complications after bortezomib in Japan.

  2008cited by this paper
• PPAR-γ agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis

  2008cited by this paper
• Cellular and molecular mechanisms of fibrosis

  2008cited by this paper
• Bronchoalveolar lavage fluid from patients with acute lung injury/acute respiratory distress syndrome induces myofibroblast differentiation

  2007influential reference
• Effects of the Protein Kinase Inhibitor, Imatinib Mesylate, on Epithelial/Mesenchymal Phenotypes: Implications for Treatment of Fibrotic Diseases

  2007cited by this paper
• Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice.

  2007cited by this paper
• Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma

  2007cited by this paper
• Proteasome inhibition induces hepatic stellate cell apoptosis

  2006cited by this paper
• Severe pulmonary complication after bortezomib treatment for multiple myeloma.

  2006cited by this paper
• Severe pulmonary complications in African-American patient after bortezomib therapy.

  2006cited by this paper
• Proapoptotic Bid is required for pulmonary fibrosis.

  2006cited by this paper
• [Cellular and molecular mechanisms of fibrosis].

  2006cited by this paper
• Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.

  2006cited by this paper
• Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

  2006cited by this paper
• Transforming growth factor beta: a central modulator of pulmonary and airway inflammation and fibrosis.

  2006influential reference
• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

  2005cited by this paper
• Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.

  2004cited by this paper
• Active transforming growth factor-β1 activates the procollagen I promoter in patients with acute lung injury

  2004cited by this paper
• Downregulation of Matrix Metalloproteinases and Collagens and Suppression of Cardiac Fibrosis by Inhibition of the Proteasome

  2004cited by this paper
• Targeted Disruption of TGF-β/Smad3 Signaling Modulates Skin Fibrosis in a Mouse Model of Scleroderma

  2004cited by this paper
• Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma.

  2004cited by this paper
• Global expression profiling of fibroblast responses to transforming growth factor-beta1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching.

  2003cited by this paper
• Attenuation of renal fibrosis by proteasome inhibition in rat obstructive nephropathy: possible role of nuclear factor kappaB.

  2003cited by this paper
• Proteasome inhibition: a new anti-inflammatory strategy

  2003cited by this paper
• Smad-dependent and Smad-independent pathways in TGF-beta family signalling.

  2003cited by this paper
• Smad-dependent and Smad-independent pathways in TGF-β family signalling

  2003cited by this paper
• The compressed feature matrix—a fast method for feature based substructure search

  2003cited by this paper
• Hyperoxia-induced Apoptosis Does Not Require Mitochondrial Reactive Oxygen Species and Is Regulated by Bcl-2 Proteins*

  2002cited by this paper
• Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression.

  2001cited by this paper
• Degradation of the Peroxisome Proliferator-activated Receptor γ Is Linked to Ligand-dependent Activation*

  2000cited by this paper
• Human Smad3 and Smad4 Are Sequence-Specific Transcription Activators

  1998cited by this paper
• Human Smad3 and Smad4 are sequence-specific transcription activators.

  1998cited by this paper
• Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors

  1992influential reference

• Pathogenic roles of immunoproteasomes in fibrosis

  2025cites this paper
• Integrating Primary and Metastatic scRNA–Seq and Bulk Data to Develop an Immune–Based Prognosis Signature for Colorectal Cancer

  2025cites this paper
• The sustained-release agent of total flavonoids of Rhizoma drynariae prepared by nano-mesoporous silica can still promote osteogenesis and angiogenesis in vitro

  2025cites this paper
• Mass spectrometry -based proteomic analysis of the skin of patients with localized scleroderma.

  2024cites this paper
• Regulation of myofibroblast dedifferentiation in pulmonary fibrosis

  2024cites this paper
• Bortezomib restrains M2 polarization and reduces CXCL16-associated CXCR6+CD4 T cell chemotaxis in bleomycin-induced pulmonary fibrosis

  2024cites this paper
• Non-peptidic immunoproteasome β5i-selective inhibitor as potential treatment for idiopathic pulmonary fibrosis: Virtual screening, hit evolution and lead identification.

  2023cites this paper
• Aspirin alleviates pulmonary fibrosis through PI3K/AKT/mTOR-mediated autophagy pathway.

  2023cites this paper
• Systemic sclerosis interstitial lung disease: unmet needs and potential solutions

  2023cites this paper
• Targeting selective E3 ligase for healing cardiac fibrosis.

  2023cites this paper
• Mitochondrial DNA-Sensing Pathogen Recognition Receptors in Systemic Sclerosis-Associated Interstitial Lung Disease: a Review

  2023cites this paper
• Evaluation of Proteasome Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis

  2022cites this paper
• Cellular and molecular diversity in rheumatic autoimmune diseases.

  2022cites this paper
• Plasma cell but not CD20-mediated B-cell depletion protects from bleomycin-induced lung fibrosis

  2022cites this paper
• Plasma cells: a feasible therapeutic target in pulmonary fibrosis?

  2022cites this paper
• Disruption of proteostasis causes IRE1 mediated reprogramming of alveolar epithelial cells

  2022cites this paper
• The Role of Myofibroblasts in Physiological and Pathological Tissue Repair.

  2022cites this paper
• Bortezomib inhibits lung fibrosis and fibroblast activation without proteasome inhibition

  2021cites this paper
• Antifibrotics in systemic sclerosis.

  2021cites this paper
• A Whole Genome-Wide Arrayed CRISPR Screen in Primary Organ Fibroblasts to Identify Regulators of Kidney Fibrosis

  2020influential citation
• A Tale of Two Proteolytic Machines: Matrix Metalloproteinases and the Ubiquitin–Proteasome System in Pulmonary Fibrosis

  2020cites this paper
• Loss of NF-E2 expression contributes to the induction of profibrotic signaling in diabetic kidneys.

  2020cites this paper
• Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies

  2020cites this paper
• Oxidative Inactivation of the Proteasome Augments Alveolar Macrophage Secretion of Vesicular SOCS3

  2020cites this paper
• The effects of miR-27a-3p-mediated Smurf2 on bleomycin A5-induced pulmonary fibrosis in rats.

  2020cites this paper
• Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD)

  2019cites this paper
• Proteasome dysfunction in alveolar type 2 epithelial cells is associated with acute respiratory distress syndrome

  2019cites this paper
• Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease

  2018cites this paper
• Bortezomib is safe in and stabilizes pulmonary function in patients with allo-HSCT-associated pulmonary CGVHD

  2018cites this paper
• The ubiquitin proteasome system as a potential therapeutic target for systemic sclerosis

  2018cites this paper
• Involvement of the ubiquitin-proteasome system in the expression of extracellular matrix genes in retinal pigment epithelial cells

  2018cites this paper
• Activation of peroxisome proliferation–activated receptor‐γ inhibits transforming growth factor‐β1‐induced airway smooth muscle cell proliferation by suppressing Smad–miR‐21 signaling

  2018cites this paper
• Novel ASK1 Inhibitor AGI-1067 Attenuates AGE-Induced Fibrotic Response by Suppressing the MKKs/p38 MAPK Pathway in Human Coronary Arterial Smooth Muscle Cells.

  2018cites this paper
• Fine-tuning the ubiquitin-proteasome system to treat pulmonary fibrosis

  2018cites this paper
• Fibrosis and Immune Dysregulation in Systemic Sclerosis

  2018cites this paper
• Ophthalmic molecular imaging and the role of the proteasome in retinal diseases

  2018cites this paper
• Lung fibrosis-associated soluble mediators and bronchoalveolar lavage from idiopathic pulmonary fibrosis patients promote the expression of fibrogenic factors in subepithelial lung myofibroblasts.

  2017cites this paper
• Lung Diseases of the Elderly: Cellular Mechanisms.

  2017cites this paper
• Inhibition of Phosphoglycerate Dehydrogenase Attenuates Bleomycin‐induced Pulmonary Fibrosis

  2017cites this paper
• The Mighty Fibroblast and Its Utility in Scleroderma Research

  2017cites this paper
• Innate Immunity in Systemic Sclerosis

  2017cites this paper
• The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1

  2017cites this paper
• Deficiency of Psgl-1 accelerates bleomycin (BLM)-induced lung fibrosis and inflammation in mice through activating PI3K/AKT.

  2017cites this paper
• Proteasome function shapes innate and adaptive immune responses.

  2016cites this paper
• Arg tyrosine kinase modulates TGF-β1 production in human renal tubular cells under high-glucose conditions

  2016cites this paper
• Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.

  2016cites this paper
• Toll‐like Receptor 9 Signaling Is Augmented in Systemic Sclerosis and Elicits Transforming Growth Factor β–Dependent Fibroblast Activation

  2016cites this paper
• Bortezomib attenuates palmitic acid-induced ER stress, inflammation and insulin resistance in myotubes via AMPK dependent mechanism.

  2016cites this paper
• Ajulemic acid exerts potent anti-fibrotic effect during the fibrogenic phase of bleomycin lung

  2016cites this paper
• Transcription Factor NF-κB: An Update on Intervention Strategies

  2016cites this paper
• Aging and Pulmonary Fibrosis.

  2016cites this paper
• D-4F, an apolipoprotein A-I mimetic, inhibits TGF-β1 induced epithelial-mesenchymal transition in human alveolar epithelial cell.

  2016cites this paper
• Therapeutic Potential of Immunoproteasome Inhibition in Duchenne Muscular Dystrophy.

  2016cites this paper
• Transforming Growth Factor (TGF)-β Promotes de Novo Serine Synthesis for Collagen Production*

  2016cites this paper
• Proteasome inhibitors as experimental therapeutics of autoimmune diseases

  2015cites this paper
• Preprocessing with Photoshop Software on Microscopic Images of A549 Cells in Epithelial-Mesenchymal Transition.

  2015cites this paper
• Lung-specific loss of α3 laminin worsens bleomycin-induced pulmonary fibrosis.

  2015cites this paper
• Aberrant TGFβ/BMP signalling in connective tissue disease associated pulmonary hypertension

  2015influential citation
• Lung-Speci fi c Loss of a 3 Laminin Worsens Bleomycin-Induced Pulmonary Fibrosis

  2015cites this paper
• Hallmarks of the ageing lung

  2015cites this paper
• Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis

  2015influential citation
• Impaired bone morphogenetic protein receptor II signaling in a transforming growth factor-β-dependent mouse model of pulmonary hypertension and in systemic sclerosis.

  2015cites this paper
• Regulation of 26S Proteasome Activity in Pulmonary Fibrosis.

  2015cites this paper
• Pathogenesis of Systemic Sclerosis

  2015cites this paper
• 2,4,6-trinitrobenzene sulfonic acid-induced chronic colitis with fibrosis and modulation of TGF-β1 signaling.

  2014cites this paper
• Novel investigational agents for the treatment of scleroderma

  2014cites this paper
• Efficient bioactive delivery of aerosolized drugs to human pulmonary epithelial cells cultured in air-liquid interface conditions.

  2014cites this paper
• Proteasomes in lungs from organ donors and patients with end-stage pulmonary diseases.

  2014cites this paper
• Current and Emerging Treatment Options in Interstitial Lung Disease

  2014cites this paper
• Protective role of bortezomib in steatotic liver ischemia/reperfusion injury through abrogation of MMP activation and YKL-40 expression.

  2014cites this paper
• Regulation of the Proteasome: Evaluating the Lung Proteasome as a New Therapeutic Target

  2014influential citation
• Propolis inhibits TGF-β1-induced epithelial-mesenchymal transition in human alveolar epithelial cells via PPARγ activation.

  2013cites this paper
• Microenvironment‐dependent homeostasis and differentiation of epidermal basal undifferentiated keratinocytes and their clinical applications in skin repair

  2013cites this paper
• Bortezomib for the treatment of previously untreated multiple myeloma.

  2013cites this paper
• Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis

  2013cites this paper
• Malfolded protein structure and proteostasis in lung diseases.

  2013cites this paper
• Molecular basis of organ fibrosis: Potential therapeutic approaches

  2013cites this paper
• Novel concepts of acute lung injury and alveolar-capillary barrier dysfunction.

  2013cites this paper
• MicroRNA-21 in Scleroderma Fibrosis and its Function in TGF-β- Regulated Fibrosis-Related Genes Expression

  2013cites this paper
• What shall we do with the damaged proteins in lung disease? Ask the proteasome!

  2012cites this paper
• Regulation of Matrix Remodeling by Peroxisome Proliferator-Activated Receptor-γ: A Novel Link Between Metabolism and Fibrogenesis

  2012cites this paper
• The relevance of photopheresis to autoreactive diseases.

  2012cites this paper
• Thorax: the Cappuccino years

  2012cites this paper
• Proteasome Inhibition Reduces Proliferation, Collagen Expression, and Inflammatory Cytokine Production in Nasal Mucosa and Polyp Fibroblasts

  2012influential citation